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Hepatologists assay liver enzymes and cardiologists structural heart proteins in serum to diagnose and monitor their patients.
This way of thinking has not quite made it into the memory clinics yet, in spite of the availability of validated cerebrospinal ﬂuid
biomarkers for key pathological events in the brain in neurodegeneration. Here, we argue that a spinal tap should be considered in
all patients who seek medical advice for memory problems and list the highly relevant clinical questions CSF analyses can address.
1.Introduction
Memory problems may be caused by a wide range of
neuropsychiatric diseases, including Alzheimer’s disease
(AD), vascular dementia (VaD), dementia with Lewy bodies,
frontotemporal dementia (FTD), to mention a few [1].
Cognitive symptoms may also arise secondary to depression,
neuroinﬂammation and various somatic illnesses. Today,
patients with memory problems seek medical advice much
earlier than 10 years ago. It is diﬃcult to diﬀerentiate
benign cognitive deﬁciencies from AD or other primary
neurodegenerative diseases. Memory problems secondary
to other diseases may also present a diagnostic chal-
lenge.
Patients with memory complaints most often undergo
extensive clinical and neuropsychological assessments, and
often also one or more brain imaging investigations. We
argue that CSF analysis should be considered in the diagnos-
tic work-up of all patients with memory problems to answer
a number of highly relevant questions discussed below. Fear
of spinal tap-related side-eﬀects should not preclude CSF
analyses, since complications are very rare in the elderly,
provided that regular precautions well known to any trained
physician are taken [2–4].
2. Does the Patient Suffer from
Brain Amyloid Pathology?
The robust association of brain amyloid pathology with AD
makes this question highly relevant. The easiest and most
cost-eﬀective way of giving it a reliable answer is to analyse
CSF for the 42 amino acid form of amyloid β (Aβ1-42).
Low CSF levels indicate retention of Aβ1-42 in the brain
parenchyma [5–8]. This seems to be the earliest biochemical
change during the course of AD [9–11]. Low levels of Aβ1-
42 may be seen Creutzfeldt-Jakob disease (CJD), also in the
absence of signiﬁcant amounts of brain amyloid pathology
[12].
3. Does the Patient Suffer from
NeuroﬁbrillaryTangle Pathology?
Tau expression is high in nonmyelinated cortical axons
where it serves as a microtubule-stabilizing protein [13].
Hyperphosphorylation of tau causes the protein to detach
from the microtubules. This process promotes axonal and
synaptic plasticity in the developing brain [14, 15], but
is pathological in the adult brain and speciﬁcally related2 International Journal of Alzheimer’s Disease
Table 1: CSF biomarkers of pathological ﬁndings in relation to diﬀerential diagnoses in memory clinic patients.
Diagnosis Amyloid pathology
(Aβ1-42)
Tangle pathology
(P-tau)
Cortical axonal
damage (T-tau)
Sub-cortical axonal
damage (NFL)
Blood-brain
barrier dysfunction
(CSF/serum
albumin ratio)
Inﬂammation
(CSF cell counts,
IgG or IgM
production)
AD Yes Yes Yes No No No
VaD No No Yes Yes Yes No
(especially in
relation to new
brain infarcts)
FTD No Yes Yes Yes No No
(but not in CSF) (mild)
LBD Yes No Yes No No No
(mild)
PD No No No No No No
PSP No Yes No Yes No No
(but not in CSF)
CJD No No Yes Yes No No
(severe) (mild to moderate)
Depression No No No No No No
Lyme disease No No No Yes Yes Yes
(mild) (especially IgM)
Multiple
sclerosis
No No No Yes No Yes
(mild in 10%) (especially IgG)
Acute stroke No No Yes Yes Yes No
Normal aging No No No No No No
Abbreviations: CSF = cerebrospinal ﬂuid; Aβ1-42 = the 42 amino acid isoform of amyloid β;P - t a u= hyperphosphorylated tau; T-tau = total tau; NFL =
neuroﬁlament light; AD = Alzheimer’s disease; VaD = vascular dementia; FTD = frontotemporal dementia; LBD = Lewy body dementia; PD = Parkinson’s
disease; PSP = progressive supranuclear palsy; CJD = Creutzfeldt-Jakob disease.
to a group of disorders referred to as tauopathies, which
includes AD and some forms of FTD [16].
Elevated CSF levels of hyperphosphorylated tau (P-tau)
protein are the most speciﬁc ﬁnding suggesting an ongoing
AD process in the brain [17]. P-tau levels correlate with
cognitive decline in patients with mild cognitive impairment
(MCI) [18] and with neocortical neuroﬁbrillary pathology
in AD [19]. The reason for the lack of P-tau increase in FTD
and other pure tauopathies such as progressive supranuclear
palsy and corticobasal degeneration is to date unknown
[20, 21].
4. Are there Biochemical Signs of
Cortical AxonalDegeneration and
How ActiveIs thisProcess?
Pathogenic processes that damage axons in the cortex
result in increased CSF levels of total tau (T-tau, i.e., all
isoforms irrespective of phosphorylation state). T-tau is
a dynamic marker of the intensity of the axonal degen-
eration/damage: the more pronounced increase, the more
intense degenerative process, the faster disease progression
[17]. Very high CSF T-tau levels are always seen in CJD
[22–25], and can be seen in stroke and brain trauma,
in which T-tau predicts clinical course and/or outcome
[26–28]. The cortical axonal degeneration in AD makes
elevated CSF T-tau an obligatory ﬁnding. Consequently,
a clinical diagnosis of AD should be reconsidered in the
absence of tau elevation. Very high levels predict a rapid
cognitive decline in AD [29–31] and short survival in DLB
[32].
Together, CSF biomarkers of amyloid pathology (Aβ1-
42), tangle pathology (P-tau) and cortical axonal degenera-
tion (T-tau) identify AD with dementia and prodromal AD
in patients with MCI with 75–95% sensitivity and speciﬁcity
[33–36].
5. Are there Biochemical Signs of
Sub-CorticalAxonalDegeneration and
H o wA c ti v eI st h isP r oc e s s ?
The best-established CSF biomarker for sub-cortical axonal
degeneration/damage is neuroﬁlament light protein (NFL).
This type of axonal degeneration is frequently seen in VaD
[37–39], FTD [40] and a number of inﬂammatory condi-
tions, including MS [41] and AIDS dementia [42]. Elevated
CSF NFL levels indicate a sub-cortical disease process and
help in diﬀerentiating pure AD from the conditions listed
above. Combined T-tau and NFL increases indicate mixed
forms of AD and cerebrovascular disease.International Journal of Alzheimer’s Disease 3
6.Isthe Blood-Brain BarrierDamaged?
The best-established biomarker for the integrity of the
blood-brain barrier is the ratio of the albumin concentration
in CSF to serum (the CSF/serum albumin ratio). Strictly
speaking, the CSF/serum albumin ratio is a direct measure of
theblood-CSFbarrier[43].However,leakingbloodvesselsin
the brain will eventually result in higher CSF/serum albumin
ratio through release of albumin to the brain interstitial
ﬂuid which communicates freely with the CSF. Typically, the
CSF/serum albumin ratio is normal in patients with pure
AD [44], whereas patients with vascular dementia generally
p r e s e n tw i t he l e v a t e da l b u m i nr a t i o[ 45]. The same ﬁnding
is often present in Lyme disease (neuroborreliosis), where
one also may ﬁnd increased numbers of CSF monocytes and
signs of immunoglobulin production within the CNS [46].
Blockage of the spinal canal which, by impairing the ﬂow
of CSF distal to the block, allows longer for equilibrium
with the circulation and so brings the composition of the
CSF nearer to that of plasma (Froin’s syndrome), results in
elevated CSF/serum albumin ratio in the absence of blood-
brain barrier damage.
7. Are there Biochemical Signs of
Neuroinﬂammation?
Basic CSF examinations of inﬂammatory activity, including
white blood cell count and general signs of IgG or IgM
production within the CNS are generally negative in AD
and other primary neurodegenerative diseases [47]. Distinct
positive results speak against pure AD and should motivate
further investigation of the patient to exclude neurobor-
reliosis, multiple sclerosis and other neuroinﬂammatory
conditions that may contribute to the cognitive symptoms.
8. Conclusions
Robust answers to the clinically relevant questions listed
above are warranted in the professional evaluation of any
patient with memory complaints. Valid CSF biomarkers
are available for amyloid pathology (Aβ1-42), neuroﬁbril-
lary pathology (P-tau), cortical axonal degeneration/damage
(T-tau), sub-cortical axonal degeneration/damage (NFL),
blood-brain barrier function (CSF/serum albumin ratio)
and neuroinﬂammation (CSF cell counts, IgG and IgM
oligoclonalbandsandconcentrations).Thebiochemicaldata
shouldbeinterpretedwithgreatcaretogetherwiththewhole
clinical picture, as well as ﬁndings in neuropsychological
testing and neuroimaging investigations. Typical changes in
relation to diﬀerent diagnostic entities are summarised in
Table 1.
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